A culprit behind brain tumor resistance to therapy

March 5, 2012

Persistent protein expression may explain why tumors return after therapy in glioblastoma patients, according to a study published on March 5th in the Journal of Experimental Medicine.

Current therapy for glioblastoma, the most prevalent in adults, includes targeting a protein called VEGF, which promotes the growth of blood vessels to the tumor. Unfortunately, in most glioblastoma patients treated with anti-VEGF drugs, tumors return shortly after treatment.

Through an international collaboration, Jiri Bartek, Jeremy Rich, and colleagues now show that these recurring tumors express a perpetually activated form of the VEGF receptor. This active VEGF receptor drives growth of the tumor even when VEGF is blocked. Directly inhibiting the VEGF receptor, however, killed the tumors and extended the survival of tumor-bearing mice that were resistant to VEGF blockade.

These results suggest that blocking this active VEGF receptor may represent an alternative treatment option in glioblastoma cases where VEGF targeting has failed.

Explore further: High VEGF signaling score tied to lung cancer prognosis

More information: Hamerlik, P., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111424

Related Stories

High VEGF signaling score tied to lung cancer prognosis

February 22, 2012

(HealthDay) -- A high vascular endothelial growth factor (VEGF) signaling score correlates with good prognosis in patients with early squamous cell carcinoma (SCC) of the lung, according to a study published online Feb. 21 ...

Recommended for you

Study sheds light on how ovarian cancer spreads

June 27, 2017

With 20,000 diagnoses each year, ovarian cancer is the ninth most common cancer and fifth leading cause of cancer death among women in the United States. So many women die from ovarian cancer because it often goes undetected ...

Cancer hijacks natural cell process to survive

June 26, 2017

Cancer tumours manipulate a natural cell process to promote their survival suggesting that controlling this mechanism could stop progress of the disease, according to new research led by the University of Oxford.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.